GlassScriptPhysician profile
Justin Keith Hamlin
NPI 1174883607
$15,445.55
in general payments reported to CMS, 2019-2025
47 companies · $2,744 in 2025
The $2,744 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,264 · 2020: $958 · 2021: $1,832 · 2022: $2,691 · 2023: $2,607 · 2024: $2,351 · 2025: $2,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,558 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,557.97 |
| Education | $143.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,475.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,403.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,044.62 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,028.72 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $992.79 | 2019-2025 | Ozempic |
| Amgen INC. | $959.06 | 2019-2025 | Evenity, Otezla, Prolia |
| Axsome Therapeutics, INC. | $911.01 | 2023-2025 | Auvelity, Sunosi |
| Lilly USA, LLC | $851.87 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $697.79 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Allergan, INC. | $482.85 | 2019-2020 | |
| Amarin Pharma, INC. | $389.95 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $359.29 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $280.68 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $262.83 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $255.84 | 2023-2024 | Ingrezza |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $233.35 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.71 | 2019-2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $200.76 | 2023-2024 | Uzedy, Austedo Xr |
| Eisai INC. | $197.26 | 2020-2021 | |
| Alkermes, INC. | $173.69 | 2023-2025 | Aristada, Lybalvi |
| Harmony Biosciences LLC | $153.80 | 2023 | Wakix |
| Novartis Pharmaceuticals Corporation | $145.36 | 2019-2024 | |
| Dexcom, INC. | $145.18 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Pfizer INC. | $141.45 | 2019-2021 | |
| Hologic Sales and Service, LLC | $138.54 | 2025 | Aptima |
| Lundbeck LLC | $137.68 | 2023-2025 | Rexulti |
| Insmed, INC. | $136.79 | 2025 | Brinsupri, Arikayce |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.53 | 2021-2025 | Caplyta |
| Glaxosmithkline, LLC. | $126.62 | 2019 | |
| Astellas Pharma US INC | $123.06 | 2019-2025 | Veozah |
| Nestle Healthcare Nutrition INC. | $107.97 | 2021-2023 | |
| Gilead Sciences, INC. | $98.62 | 2019 | |
| Collegium Pharmaceutical, INC. | $72.27 | 2021-2025 | Xtampza, Belbuca |
| Takeda Pharmaceuticals U.S.A., INC. | $52.46 | 2019-2025 | Trintellix |
| Aimmune Therapeutics, INC. | $48.64 | 2024-2025 | Zenpep |
| Sumitomo Pharma America, INC. | $42.94 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $36.83 | 2019 | |
| Alvogen INC | $29.27 | 2024 | Teriparatide |
| Mylan Specialty L.P. | $24.35 | 2021 | |
| Exact Sciences Corporation | $19.62 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $19.27 | 2024 | Quviviq |
| Braeburn INC. | $18.38 | 2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $16.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2022 | |
| Circassia INC. | $14.81 | 2019 | |
| Medtronic Minimed, INC. | $14.03 | 2019 | |
| Viatris Specialty LLC | $13.97 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Hamlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.